

**DAFTAR PUSTAKA**

- ACC/AHA Task Force. 2013. ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. *Circ.*
- ADA (2017) 'STANDARDS OF MEDICAL CARE IN DIABETES — 2017 Standards of Medical Care in Diabetes d 2017', 40(January).
- Athyros, V. G. *et al.* (2018) 'Diabetes and lipid metabolism', *Hormones*. *Hormones*, 17(1), pp. 61–67. doi: 10.1007/s42000-018-0014-8.
- Baynest, H. W. (2015) 'Classification , Pathophysiology , Diagnosis and Management of Diabetes', *Journal of Diabetes and Metabolism*, 6(5). doi: 10.4172/2155-6156.1000541.
- Bergheanu, S. C., Bodde, M. C. and Jukema, J. W. (2017) 'Pathophysiology and treatment of atherosclerosis: Current view and future perspective on lipoprotein modification treatment', *Netherlands Heart Journal*, 25(4), pp. 231–242. doi: 10.1007/s12471-017-0959-2.
- Cai, A., Zhou, Y. and Li, Li. (2015) 'Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins', *American Heart Association/ American Stroke Association*, pp. 1–9. doi: 10.1161/JAHA.115.002113.
- Chawla, A., Chawla, R. and Jaggi, S. (2016) 'Microvascular and macrovascular complications in diabetes mellitus: Distinct or continuum?', *Indian Journal of Endocrinology and Metabolism*, 20(4), p. 546. doi: 10.4103/2230-8210.183480.
- Chehade, J. M., Gladysz, M. and Mooradian, A. D. (2013) 'Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology, and management', *Drugs*, 73(4), pp. 327–339. doi: 10.1007/s40265-013-0023-5.

- Cho, N. H. *et al.* (2018) 'IDF Diabetes Atlas : Global estimates of diabetes prevalence for 2017 and projections for 2045', *Diabetes Research and Clinical Practice*. Elsevier B.V., 138, pp. 271–281. doi: 10.1016/j.diabres.2018.02.023.
- Colhoun, H. M. *et al.* (2004) 'Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.', *Lancet*, 364(9435), p. 685. doi: 10.1016/S0140-6736(04)16895-5.
- CTT (2005) 'Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins', *Lancet*, 366(9493), pp. 1267–1278. doi: 10.1016/S0140-6736(05)67394-1.
- Dasgupta, A. and Wahed, A. (2014) 'Carbohydrate Metabolism, Diabetes, and Hypoglycemia', *Clinical Chemistry, Immunology and Laboratory Quality Control*, pp. 107–126. doi: 10.1016/B978-0-12-407821-5.00007-3.
- Diamantis, E. *et al.* (2017) 'The Anti-Inflammatory Effects of Statins on Coronary Artery Disease : An Updated Review of the Literature', pp. 209–216. doi: 10.2174/1573403X13666170426104611.
- Donath, M. Y. and Shoelson, S. E. (2011) 'Type 2 diabetes as an inflammatory disease', *Nature Reviews Immunology*. Nature Publishing Group, 11(2), pp. 98–107. doi: 10.1038/nri2925.
- Feingold, K. R. and Grunfeld, C. (2018) 'Diabetes and Dyslipidemia', *NCBI Bookshelf*, pp. 1–38.
- Knopp, R. H. *et al.* (2006) 'Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)', *Diabetes Care*, 29(7), pp. 1478–1485. doi: 10.2337/dc05-2415.

- Margaritis, M., Channon, K. M. and Antoniades, C. (2014) 'Statins as Regulators of Redox State in the Vascular Endothelium : Beyond Lipid Lowering', 20(8), pp. 1198–1215. doi: 10.1089/ars.2013.5430.
- Mclaren, J. E. *et al.* (2011) 'Cytokines , macrophage lipid metabolism and foam cells : Implications for cardiovascular disease therapy', *Progress in Lipid Research*. Elsevier Ltd, 50(4), pp. 331–347. doi: 10.1016/j.plipres.2011.04.002.
- Morgantini, C. *et al.* (2011) 'Anti-in fl ammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes', (July). doi: 10.2337/db11-0378.
- Pamukcu, B., Lip, G. Y. H. and Shantsila, E. (2011) 'The nuclear factor – kappa B pathway in atherosclerosis : A potential therapeutic target for atherothrombotic vascular disease', *Thrombosis Research*. Elsevier B.V., 128(2), pp. 117–123. doi: 10.1016/j.thromres.2011.03.025.
- Paneni, F. *et al.* (2013) 'Clinical update Diabetes and vascular disease : pathophysiology , clinical consequences , and medical therapy : part I'. doi: 10.1093/eurheartj/eht149.
- Saeedi, R. and Frohlich, J. (2016) 'Lipoprotein ( a ), an independent cardiovascular risk marker', *Clinical Diabetes and Endocrinology*. Clinical Diabetes and Endocrinology, pp. 1–6. doi: 10.1186/s40842-016-0024-x.
- Save, V. *et al.* (2006) 'Effect of Atorvastatin on Vipul', *Journal of Cardiovascular Pharmacology and Therapeutics*, pp. 262–270.
- Schachter, M. (2004) 'Chemical , pharmacokinetic and pharmacodynamic properties of statins : an update', 19, pp. 117–125. doi: 10.1111/j.1472-8206.2004.00299.x.

- Schofield, J. D. *et al.* (2016) 'Diabetes Dyslipidemia', *Diabetes Therapy*. Springer Healthcare, 7(2), pp. 203–219. doi: 10.1007/s13300-016-0167-x.
- Serasanambati, M. R. and Chilakapati, S. R. (2016) 'Function of Nuclear Factor kappa B ( NF-kB ) in human diseases-A Review', *South Indian Journal of BIOLOGICAL SCIENCES*, (October). doi: 10.22205/sijbs/2016/v2/i4/103443.
- Sever, P. S. *et al.* (2003) 'Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomise', *The Lancet*, 361(9364), p. 1158. doi: 10.1016/S0016-2361(01)00124-7.
- Su, Y. *et al.* (2010) 'Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with Type 2 Diabetes Mellitus', *Journal of Cardiovascular Pharmacology*, 55(1), pp. 21–25. doi: 10.1002/clc.20724.
- Tousoulis, D. *et al.* (2014) 'Innate and adaptiveinflammation as a therapeutic target in vascular disease: The emerging role of statins', *Journal of the American College of Cardiology*. Elsevier Ltd. doi: 10.1016/j.jacc.2014.01.054.
- Wu, L. and Parhofer, K. G. (2014) 'Diabetic dyslipidemia', *Metabolism: Clinical and Experimental*. Elsevier Inc., 63(12), pp. 1469–1479. doi: 10.1016/j.metabol.2014.08.010.
- Ye, Y., Zhao, X. and Zhang, S. (2015) 'Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients', 128(2), pp. 259–266. doi: 10.4103/0366-6999.149226.
- Zhao, J. *et al.* (2014) 'The Many Roles of Statins in Ischemic Stroke', pp. 564–574.